FIELD: medicine.
SUBSTANCE: method for identifying PirB/LILRB antagonist involves the contact of an examined agent and a receptor complex which contains PirB/LILRB and myeline or myeline-associated protein or its fragment, and detecting an ability of the examined agent to inhibit a reaction of PirB/LILRB and myeline-associated protein or its fragment. Said method enables decreased inhibition and stimulation of axon growth in a CNS neuron. Besides, the invention refers to a method of treating a neural involvement in a subject and a method of maintaining the CNS neuron viable involving the contact of said neuron and PirB/LILRB antagonist.
EFFECT: reduced activity of said antagonist effectively destroys the myeline-associated inhibitory path with accelerating neuronal regeneration.
35 cl, 1 tbl, 8 ex, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PURIFIED IMMUNOGENIC PROTEIN, ITS FRAGMENTS AND DERIVATIVES | 1999 |
|
RU2304585C2 |
| METHODS FOR MAKING POLYCLONAL ANTIBODIES, ANTISERUM CONTAINING POLYCLONAL ANTIBODIES, AND METHODS FOR IMMUNISATION | 1999 |
|
RU2358982C2 |
| MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
| DPPIV-COGNATED NEW SERINE PROTEASE GENE | 2001 |
|
RU2305133C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2010 |
|
RU2539034C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| ADVANCED GLYCATION END PRODUCT (RAGE) RECEPTOR ANTIBODIES AND USING THEM | 2009 |
|
RU2518351C2 |
| TREATMENT OF INTERSTITIAL CYSTITIS | 2008 |
|
RU2570559C2 |
| COMPOSITIONS AND METHODS FOR DIAGNOSTICS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITES DEGENERATION | 2013 |
|
RU2644337C2 |
| ANTI-Nogo ANTIBODIES ("11C7") AND THEIR APPLICATION IN PHARMACEUTICS | 2003 |
|
RU2350623C2 |
